AmacaThera is commercialising a novel biomaterial developed by the Shoichet Laboratory at University of Toronto.  Molly Shoichet’s laboratory has developed HAMC, a platform technology that can be used to increase the length of time a drug is effective. HAMC is a reversible and fast gelling physical blend of hyaluronan (HA) and methyl cellulose (MC) that liquefies under shear force and re-gels immediately on extrusion – HAMC can be injected from a syringe into small spaces and gels at body temperature. Using pain medication formulated in HAMC we are investigating the reduction of pain after both general surgery and back surgery.

AmacaThera | Redefining How Therapeutics are Delivered

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Team Members

Mike Cooke

Molly Shoichet